



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 09th February, 2022

To,
BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai – 400001

Ref.: Company Code: 541096

Dear Sir / Madam,

Sub: Outcome of the Board Meeting and Submission of Unaudited Financial Results for the Quarter ended 31st December, 2021.

In compliance of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on 09th February, 2022 has considered and approved the Unaudited Financial Results for the Quarter ended 31st December, 2021 and taken on record Limited Review Report issued by the Statutory Auditors of the Company.

In this respect, we hereby enclose following:

1. Unaudited Financial Results for the Quarter ended 31st December, 2021.
2. Limited Review Report on the said Financial Results.

The meeting of Board of Directors commenced at 01.30 p.m. and concluded at 02:00 p.m.

Request you to please take the same on record.

Thanking You,

FOR BHARAT PARENTERALS LIMITED

Lubhanshi Jhalani
Company Secretary



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2021

(Amount Rs. in lakhs)

Sr. No.	Particular	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	3,846	6,040	4,955	15,970	16,305	20,367
	B. Other Income	136	252	259	564	713	867
	Total income	3,983	6,292	5,214	16,534	17,018	21,234
2	Expenses						
	A. Cost of materials consumed	2,438	3,735	2,588	10,005	10,198	12,713
	B. Purchase of Stock in-Trade	4	43	294	133	395	502
	C. Changes in inventories of finished goods, work-in progress and stock-in trade	(10)	114	414	6	142	188
	D. Employee benefit expense	373	391	344	1,142	1,030	1,439
	E. Finance costs	21	15	17	65	37	76
	F. Depreciation and amortisation expense	164	172	164	510	434	603
	G. Other Expenses	757	745	749	2,317	2,335	3,011
	Total expenses	3,747	5,215	4,569	14,178	14,572	18,532
3	Total profit before tax	236	1,077	644	2,356	2,447	2,702
4	Tax expense						
	Current tax	82	288	171	649	659	732
	Deferred tax	8	(13)	(44)	(18)	(14)	(28)
	Short / (Excess) provision of tax in respect of earlier years	-	-	(23)	-	(23)	(23)
	Total tax expenses	90	275	103	632	622	681
5	Net Profit / (loss) for period	146	802	541	1,724	1,825	2,021
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	5	6	1	16	4	21
	income tax relating to Remeasurement of Defined benefit plans	(1)	(2)	(0)	(4)	(1)	(5)
	Other comprehensive Income for the year, net of taxes	4	4	1	12	3	16
7	Total Comprehensive Income for the period	150	806	542	1,736	1,828	2,037
8	Equity						
	a) Equity Share Capital (Face Value of Rs. 10/- each)						573
	b) Other Equity						13,821
9	Earnings per share						
	Basic (Rs.)	2.55	13.99	9.44	30.09	31.85	35.27
	Diluted (Rs.)	2.55	13.99	9.44	30.09	31.85	35.27

See accompanying notes to the Financial Results

- The Company has only one segment of activity, namely "Pharmaceuticals,".
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director

Place : Vadodara

Date : 09th February, 2022



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2021

(Amount Rs. in lakhs)

Sr. No.	Particular	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	3,846	6,040	4,955	15,970	16,403	20,464
	B. Other Income	131	252	260	559	714	867
	Total income	3,977	6,292	5,214	16,529	17,117	21,332
2	Expenses						
	A. Cost of materials consumed	2,438	3,735	2,588	10,005	10,198	12,713
	B. Purchase of Stock-in-Trade	4	43	294	133	426	533
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10)	114	414	6	135	180
	D. Employee benefit expense	376	394	344	1,148	1,067	1,475
	E. Finance costs	21	15	17	65	37	77
	F. Depreciation and amortisation expense	164	172	165	510	434	603
	G. Other Expenses	770	755	749	2,345	2,348	3,038
	Total expenses	3,762	5,228	4,569	14,213	14,644	18,619
3	Total profit before tax	215	1,064	645	2,316	2,472	2,712
4	Tax expense						
	Current tax	82	288	171	649	659	732
	Deferred tax	8	(13)	(44)	(18)	(14)	(28)
	Short / (Excess) provision of tax in respect of earlier years	-	-	(23)	-	(23)	(23)
	Total tax expenses	90	275	103	632	622	681
5	Net Profit / (loss) for period	125	789	542	1,684	1,850	2,032
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	5	6	1	16	4	21
	Income tax relating to Remeasurement of Defined benefit plans	(1)	(2)	(0)	(4)	(1)	(5)
	Other comprehensive Income for the year, net of taxes	4	4	1	12	3	16
7	Total Comprehensive Income for the period	129	793	543	1,696	1,853	2,047
	Net Profit attributable to:						
	Owners of the company	133	795	541	1,701	1,850	2,039
	Non Controlling Interest	(8)	(6)	-	(17)	-	(7)
	Other Comprehensive Income attributable to:						
	Owners of the company	4	4	1	12	3	16
	Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income for the period						
	Owners of the company	137	799	542	1,713	1,853	2,055
	Non Controlling Interest	(8)	(6)	-	(17)	-	(7)
8	Equity						
	a) Equity Share Capital (Face Value of Rs. 10/- each)						573
	b) Other Equity						13,814
9	Earnings per share						
	Basic (Rs.)	2.32	13.88	9.46	29.69	32.29	35.59
	Diluted (Rs.)	2.32	13.88	9.46	29.69	32.29	35.59

See accompanying notes to the Financial Results

- The Company has only one segment of activity, namely "Pharmaceuticals."
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 09th February, 2022



Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Bharat Parenterals Limited ("the Company") for the quarter ended 31st December, 2021 and year to date from 01st April, 2021 to 31st December, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah



Alok Shah

Partner

Membership No. 042005

Place: Vadodara

Date: 09th February, 2022

UDIN: 22042005AAYRIO3344

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Bharat Parenterals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2021 and year to date from 01st April, 2021 to 31st December, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinkhwar Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. The statement includes results of the following entity:
 - i. Innoxel Lifesciences Private Limited
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect total revenue of Rs. Nil and Rs. Nil, total net loss after tax of Rs. 15.78 lakhs and Rs. 34.50 lakhs and total comprehensive loss of Rs. 15.78 lakhs and Rs. 34.50 lakhs for the quarter ended 31st December, 2021 and the period ended on that day respectively. These financial results have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For **CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036





Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 09th February, 2022

UDIN : 22042005AAYRZC9254